Top

Published in:

Open Access 01-04-2019 | Hyperparathyroidism | Therapy in Practice

Management of Post-transplant Hyperparathyroidism and Bone Disease

Authors: Rowena Delos Santos, Ana Rossi, Daniel Coyne, Thin Thin Maw

Published in: Drugs | Issue 5/2019

Abstract

Significant advances in immunosuppressive therapies have been made in renal transplantation, leading to increased allograft and patient survival. Despite improvement in overall patient survival, patients continue to require management of persistent post-transplant hyperparathyroidism. Medications that treat persistent hyperparathyroidism include vitamin D, vitamin D analogues, and calcimimetics. Medication side effects such as hypocalcemia or hypercalcemia, and adynamic bone disease, may lead to a decrease in the drugs. When medical management fails to control persistent post-transplant hyperparathyroidism, treatment is a parathyroidectomy. Surgical techniques are not uniform between centers and surgeons. Undergoing the surgery may include a subtotal technique or a technique including total parathyroid gland resection with partial heterotopic gland reimplantation. In addition, there are possible post-surgical complications. The ideal treatment for persistent post-transplant hyperparathyroidism is the treatment and prevention of the condition while patients are being managed for their late-stage chronic kidney disease and end-stage renal disease.

Wang JH, Skeans MA, Israni AK. Current status of kidney transplant outcomes: dying to survive. Adv Chronic Kidney Dis. 2016;23(5):281–6. https://doi.org/10.1053/j.ackd.2016.07.001.CrossRefPubMed

Evenepoel P, Claes K, Kuypers D, Maes B, Bammens B, Vanrenterghem Y. Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre study. Nephrol Dial Transplant. 2004;19(5):1281–7. https://doi.org/10.1093/ndt/gfh128.CrossRefPubMed

Reinhardt W, Bartelworth H, Jockenhovel F, Schmidt-Gayk H, Witzke O, Wagner K, et al. Sequential changes of biochemical bone parameters after kidney transplantation. Nephrol Dial Transplant. 1998;13(2):436–42.CrossRefPubMed

Sprague SM, Belozeroff V, Danese MD, Martin LP, Olgaard K. Abnormal bone and mineral metabolism in kidney transplant patients—a review. Am J Nephrol. 2008;28(2):246–53. https://doi.org/10.1159/000110875.CrossRefPubMed

Copley JB, Wuthrich RP. Therapeutic management of post-kidney transplant hyperparathyroidism. Clin Transplant. 2011;25(1):24–39. https://doi.org/10.1111/j.1399-0012.2010.01287.x.CrossRefPubMed

Messa P, Sindici C, Cannella G, Miotti V, Risaliti A, Gropuzzo M, et al. Persistent secondary hyperparathyroidism after renal transplantation. Kidney Int. 1998;54(5):1704–13. https://doi.org/10.1046/j.1523-1755.1998.00142.x.CrossRefPubMed

Torres A, Rodriguez AP, Concepcion MT, Garcia S, Rufino M, Martin B, et al. Parathyroid function in long-term renal transplant patients: importance of pre-transplant PTH concentrations. Nephrol Dial Transplant. 1998;13(Suppl 3):94–7.CrossRefPubMed

Muirhead N, Zaltman JS, Gill JS, Churchill DN, Poulin-Costello M, Mann V, et al. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice. Clin Transplant. 2014;28(2):161–5. https://doi.org/10.1111/ctr.12291.CrossRefPubMed

Santini SA, Carrozza C, Vulpio C, Capoluongo E, Luciani G, Lulli P, et al. Assessment of parathyroid function in clinical practice: which parathyroid hormone assay is better? Clin Chem. 2004;50(7):1247–50. https://doi.org/10.1373/clinchem.2003.030759.CrossRefPubMed

10.

Isakova T, Wahl P, Vargas GS, Gutierrez OM, Scialla J, Xie H, et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int. 2011;79(12):1370–8. https://doi.org/10.1038/ki.2011.47.CrossRefPubMedPubMedCentral

11.

Wolf M, Weir MR, Kopyt N, Mannon RB, Von Visger J, Deng H, et al. A prospective cohort study of mineral metabolism after kidney transplantation. Transplantation. 2016;100(1):184–93. https://doi.org/10.1097/tp.0000000000000823.CrossRefPubMed

12.

Lewin E, Huan J, Olgaard K. Parathyroid growth and suppression in renal failure. Semin Dial. 2006;19(3):238–45. https://doi.org/10.1111/j.1525-139X.2006.00161.x.CrossRefPubMed

13.

Bouquegneau A, Salam S, Delanaye P, Eastell R, Khwaja A. Bone disease after kidney transplantation. Clin J Am Soc Nephrol. 2016;11(7):1282–96. https://doi.org/10.2215/cjn.11371015.CrossRefPubMedPubMedCentral

14.

Perrin P, Caillard S, Javier RM, Braun L, Heibel F, Borni-Duval C, et al. Persistent hyperparathyroidism is a major risk factor for fractures in the five years after kidney transplantation. Am J Transplant. 2013;13(10):2653–63. https://doi.org/10.1111/ajt.12425.CrossRefPubMed

15.

Pihlstrom H, Dahle DO, Mjoen G, Pilz S, Marz W, Abedini S, et al. Increased risk of all-cause mortality and renal graft loss in stable renal transplant recipients with hyperparathyroidism. Transplantation. 2015;99(2):351–9. https://doi.org/10.1097/tp.0000000000000583.CrossRefPubMed

16.

Coyne DW, Delos Santos R. Evaluating the safety and rationale for cinacalcet posttransplant hyperparathyroidism and hypercalcemia. Am J Transplant. 2014;14(11):2446–7. https://doi.org/10.1111/ajt.12913.CrossRefPubMed

17.

Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L, et al. Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int. 2017;92(1):26–36. https://doi.org/10.1016/j.kint.2017.04.006.CrossRefPubMed

18.

Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutierrez OM, et al. KDOQI US commentary on the 2017 KDIGO clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis. 2017;70(6):737–51. https://doi.org/10.1053/j.ajkd.2017.07.019.CrossRefPubMed

19.

Burton JO, Goldsmith DJ, Ruddock N, Shroff R, Wan M. Renal association commentary on the KDIGO (2017) clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of CKD-MBD. BMC Nephrol. 2018;19(1):240. https://doi.org/10.1186/s12882-018-1037-8.CrossRefPubMedPubMedCentral

20.

NICE. National Institute for Health and Care Excellence. Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy. Technology appraisal guidance TA117. 2007. Retrieved from https://www.nice.org.uk/guidance/ta117.

21.

Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apheresis Dial. 2013;17(3):247–88. https://doi.org/10.1111/1744-9987.12058.CrossRef

22.

CARI. Caring for Australasians with Renal Impairment. KHA-CARI adaptation of the KDIGO guideline for the care of kidney transplant recipients. 2012. Retrieved from http://www.cari.org.au/Transplantation/transplantation%20care%20of%20recipients/transplant_care_of_recipients.html.

23.

Torres A, Garcia S, Gomez A, Gonzalez A, Barrios Y, Concepcion MT, et al. Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantation. Kidney Int. 2004;65(2):705–12. https://doi.org/10.1111/j.1523-1755.2004.00432.x.CrossRefPubMed

24.

Hahn TJ, Halstead LR, Baran DT. Effects off short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentrations in man. J Clin Endocrinol Metab. 1981;52(1):111–5. https://doi.org/10.1210/jcem-52-1-111.CrossRefPubMed

25.

Lieben L, Carmeliet G, Masuyama R. Calcemic actions of vitamin D: effects on the intestine, kidney and bone. Best Pract Res Clin Endocrinol Metab. 2011;25(4):561–72. https://doi.org/10.1016/j.beem.2011.05.008.CrossRefPubMed

26.

Wissing KM, Broeders N, Moreno-Reyes R, Gervy C, Stallenberg B, Abramowicz D. A controlled study of vitamin D3 to prevent bone loss in renal-transplant patients receiving low doses of steroids. Transplantation. 2005;79(1):108–15.CrossRefPubMed

27.

Amer H, Griffin MD, Stegall MD, Cosio FG, Park WD, Kremers WK, et al. Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial. Am J Transplant. 2013;13(6):1576–85. https://doi.org/10.1111/ajt.12227.CrossRefPubMed

28.

Trillini M, Cortinovis M, Ruggenenti P, Reyes Loaeza J, Courville K, Ferrer-Siles C, et al. Paricalcitol for secondary hyperparathyroidism in renal transplantation. J Am Soc Nephrol. 2015;26(5):1205–14. https://doi.org/10.1681/asn.2013111185.CrossRefPubMed

29.

de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet. 2010;376(9752):1543–51. https://doi.org/10.1016/s0140-6736(10)61032-x.CrossRefPubMed

30.

Cruzado JM, Lauzurica R, Pascual J, Marcen R, Moreso F, Gutierrez-Dalmau A, et al. Paricalcitol versus calcifediol for treating hyperparathyroidism in kidney transplant recipients. Kidney Int Rep. 2018;3(1):122–32. https://doi.org/10.1016/j.ekir.2017.08.016.CrossRefPubMed

31.

Boudville NC, Hodsman AB. Renal function and 25-hydroxyvitamin D concentrations predict parathyroid hormone levels in renal transplant patients. Nephrol Dial Transplant. 2006;21(9):2621–4. https://doi.org/10.1093/ndt/gfl201.CrossRefPubMed

32.

Rodriguez M, Nemeth E, Martin D. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol. 2005;288(2):F253–64. https://doi.org/10.1152/ajprenal.00302.2004.CrossRefPubMed

33.

Morales E, Gutierrez E, Andres A. Treatment with calcimimetics in kidney transplantation. Transplant Revi (Orlando, Fla). 2010;24(2):79–88. https://doi.org/10.1016/j.trre.2010.01.001.CrossRef

34.

Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25. https://doi.org/10.1056/NEJMoa031633.CrossRefPubMed

35.

Leonard N, Brown JH. Persistent and symptomatic post-transplant hyperparathyroidism: a dramatic response to cinacalcet. Nephrol Dial Transplant. 2006;21(6):1736. https://doi.org/10.1093/ndt/gfk018.CrossRefPubMed

36.

Serra AL, Savoca R, Huber AR, Hepp U, Delsignore A, Hersberger M, et al. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients. Nephrol Dial Transplant. 2007;22(2):577–83. https://doi.org/10.1093/ndt/gfl560.CrossRefPubMed

37.

Schwarz A, Merkel S, Leitolf H, Haller H. The effect of cinacalcet on bone remodeling and renal function in transplant patients with persistent hyperparathyroidism. Transplantation. 2011;91(5):560–5. https://doi.org/10.1097/TP.0b013e3182079431.CrossRefPubMed

38.

Evenepoel P, Cooper K, Holdaas H, Messa P, Mourad G, Olgaard K, et al. A randomized study evaluating cinacalcet to treat hypercalcemia in renal transplant recipients with persistent hyperparathyroidism. Am J Transplant. 2014;14(11):2545–55.CrossRefPubMed

39.

Zavvos V, Fyssa L, Papasotiriou M, Papachristou E, Ntrinias T, Savvidaki E, et al. Long-term use of cinacalcet in kidney transplant recipients with hypercalcemic secondary hyperparathyroidism: a single-center prospective study. Exp Clin Transplant. 2018;16(3):287–93. https://doi.org/10.6002/ect.2016.0342.CrossRefPubMed

40.

Courbebaisse M, Diet C, Timsit MO, Mamzer MF, Thervet E, Noel LH, et al. Effects of cinacalcet in renal transplant patients with hyperparathyroidism. Am J Nephrol. 2012;35(4):341–8. https://doi.org/10.1159/000337526.CrossRefPubMed

41.

Evenepoel P, Sprangers B, Lerut E, Bammens B, Claes K, Kuypers D, et al. Mineral metabolism in renal transplant recipients discontinuing cinacalcet at the time of transplantation: a prospective observational study. Clin Transplant. 2012;26(3):393–402. https://doi.org/10.1111/j.1399-0012.2011.01524.x.CrossRefPubMed

42.

Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. Effect of cinacalcet cessation in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2007;22(8):2362–5. https://doi.org/10.1093/ndt/gfm270.CrossRefPubMed

43.

Block GA, Bushinsky DA, Cheng S, Cunningham J, Dehmel B, Drueke TB, et al. Effect of etelcalcetide vs cinacalcet on serum parathyroid hormone in patients receiving hemodialysis with secondary hyperparathyroidism: a randomized clinical trial. JAMA. 2017;317(2):156–64. https://doi.org/10.1001/jama.2016.19468.CrossRefPubMed

44.

Kruse AE, Eisenberger U, Frey FJ, Mohaupt MG. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism. Nephrol Dial Transplant. 2005;20(7):1311–4. https://doi.org/10.1093/ndt/gfh924.CrossRefPubMed

45.

Borchhardt KA, Diarra D, Sulzbacher I, Benesch T, Haas M, Sunder-Plassmann G. Cinacalcet decreases bone formation rate in hypercalcemic hyperparathyroidism after kidney transplantation. Am J Nephrol. 2010;31(6):482–9. https://doi.org/10.1159/000304180.CrossRefPubMed

46.

Malluche HH, Monier-Faugere MC, Wang G, Fraza OJ, Charytan C, Coburn JW, et al. An assessment of cinacalcet HCl effects on bone histology in dialysis patients with secondary hyperparathyroidism. Clin Nephrol. 2008;69(4):269–78.CrossRefPubMed

47.

Grotz W, Nagel C, Poeschel D, Cybulla M, Petersen KG, Uhl M, et al. Effect of ibandronate on bone loss and renal function after kidney transplantation. J Am Soc Nephrol. 2001;12(7):1530–7.PubMed

48.

Haas M, Leko-Mohr Z, Roschger P, Kletzmayr J, Schwarz C, Mitterbauer C, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63(3):1130–6. https://doi.org/10.1046/j.1523-1755.2003.00816.x.CrossRefPubMed

49.

Fan SL, Almond MK, Ball E, Evans K, Cunningham J. Pamidronate therapy as prevention of bone loss following renal transplantation. Kidney Int. 2000;57(2):684–90. https://doi.org/10.1046/j.1523-1755.2000.00890.x.CrossRefPubMed

50.

Abediazar S, Nakhjavani MR. Effect of alendronate on early bone loss of renal transplant recipients. Transplant Proc. 2011;43(2):565–7. https://doi.org/10.1016/j.transproceed.2011.01.025.CrossRefPubMed

51.

Torregrosa JV, Fuster D, Pedroso S, Diekmann F, Campistol JM, Rubi S, et al. Weekly risedronate in kidney transplant patients with osteopenia. Transplant Int. 2007;20(8):708–11. https://doi.org/10.1111/j.1432-2277.2007.00501.x.CrossRef

52.

Conley E, Muth B, Samaniego M, Lotfi M, Voss B, Armbrust M, et al. Bisphosphonates and bone fractures in long-term kidney transplant recipients. Transplantation. 2008;86(2):231–7. https://doi.org/10.1097/TP.0b013e318176b40f.CrossRefPubMedPubMedCentral

53.

Grotz WH, Rump LC, Niessen A, Schmidt-Gayk H, Reichelt A, Kirste G, et al. Treatment of osteopenia and osteoporosis after kidney transplantation. Transplantation. 1998;66(8):1004–8.CrossRefPubMed

54.

Palmer SC, Strippoli GF, McGregor DO. Interventions for preventing bone disease in kidney transplant recipients: a systematic review of randomized controlled trials. Am J Kidney Dis. 2005;45(4):638–49.CrossRefPubMed

55.

Toth-Manikowski SM, Francis JM, Gautam A, Gordon CE. Outcomes of bisphosphonate therapy in kidney transplant recipients: a systematic review and meta-analysis. Clin Transplant. 2016;30(9):1090–6. https://doi.org/10.1111/ctr.12792.CrossRefPubMed

56.

Versele EB, Van Laecke S, Dhondt AW, Verbeke F, Vanholder R, Van Biesen W, et al. Bisphosphonates for preventing bone disease in kidney transplant recipients: a meta-analysis of randomized controlled trials. Transplant Int. 2016;29(2):153–64. https://doi.org/10.1111/tri.12691.CrossRef

57.

Dore RK. The RANKL pathway and denosumab. Rheum Dis Clin N Am. 2011;37(3):433–52. https://doi.org/10.1016/j.rdc.2011.07.004.CrossRef

58.

Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–65. https://doi.org/10.1056/NEJMoa0809493.CrossRefPubMed

59.

Jamal SA, Ljunggren O, Stehman-Breen C, Cummings SR, McClung MR, Goemaere S, et al. Effects of denosumab on fracture and bone mineral density by level of kidney function. J Bone Mineral Res. 2011;26(8):1829–35. https://doi.org/10.1002/jbmr.403.CrossRef

60.

Bonani M, Frey D, Brockmann J, Fehr T, Mueller TF, Saleh L, et al. Effect of twice-yearly denosumab on prevention of bone mineral density loss in de novo kidney transplant recipients: a randomized controlled trial. Am J Transplant. 2016;16(6):1882–91. https://doi.org/10.1111/ajt.13692.CrossRefPubMed

61.

Bonani M, Meyer U, Frey D, Graf N, Bischoff-Ferrari HA, Wuthrich RP. Effect of denosumab on peripheral compartmental bone density, microarchitecture and estimated bone strength in de novo kidney transplant recipients. Kidney Blood Press Res. 2016;41(5):614–22. https://doi.org/10.1159/000447930.CrossRefPubMed

62.

Bonani M, Frey D, de Rougemont O, Mueller NJ, Mueller TF, Graf N, et al. Infections in de novo kidney transplant recipients treated with the RANKL inhibitor denosumab. Transplantation. 2017;101(9):2139–45. https://doi.org/10.1097/tp.0000000000001547.CrossRefPubMed

63.

Brunova J, Kratochvilova S, Stepankova J. Osteoporosis therapy with denosumab in organ transplant recipients. Front Endocrinol. 2018;9:162. https://doi.org/10.3389/fendo.2018.00162.CrossRef

64.

Torregrosa JV. Dramatic increase in parathyroid hormone and hypocalcaemia after denosumab in a kidney transplanted patient. Clin Kidney J. 2013;6(1):122. https://doi.org/10.1093/ckj/sfs158.CrossRefPubMed

65.

Ungprasert P, Cheungpasitporn W, Srivali N, Kittanamongkolchai W, Bischof EF. Life-threatening hypocalcemia associated with denosumab in a patient with moderate renal insufficiency. Am J Emerg Med. 2013;31(4):756-e1. https://doi.org/10.1016/j.ajem.2012.11.011.CrossRef

66.

Farinola N, Kanjanapan Y. Denosumab-induced hypocalcaemia in high bone turnover states of malignancy and secondary hyperparathyroidism from renal failure. Internal Med J. 2013;43(11):1243–6. https://doi.org/10.1111/imj.12283.CrossRef

67.

Ivanov P, Khedr M. Prolonged hypocalcaemia following a single dose of 60 mg denosumab in two patients with CKD 4/5 on cinacalcet treatment for tertiary hyperparathyroidism. Clin Kid J. 2013;6(2):245. https://doi.org/10.1093/ckj/sft014.CrossRef

68.

Cejka D, Benesch T, Krestan C, Roschger P, Klaushofer K, Pietschmann P, et al. Effect of teriparatide on early bone loss after kidney transplantation. Am J Transplant. 2008;8(9):1864–70. https://doi.org/10.1111/j.1600-6143.2008.02327.x.CrossRefPubMed

69.

Wilson LM, Rebholz CM, Jirru E, Liu MC, Zhang A, Gayleard J, et al. Benefits and harms of osteoporosis medications in patients with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2017;166(9):649–58. https://doi.org/10.7326/m16-2752.CrossRefPubMed

70.

Evenepoel P, Claes K, Kuypers DR, Debruyne F, Vanrenterghem Y. Parathyroidectomy after successful kidney transplantation: a single centre study. Nephrol Dial Transplant. 2007;22(6):1730–7. https://doi.org/10.1093/ndt/gfm044.CrossRefPubMed

71.

Lorenz K, Bartsch DK, Sancho JJ, Guigard S, Triponez F. Surgical management of secondary hyperparathyroidism in chronic kidney disease—a consensus report of the European Society of Endocrine Surgeons. Langenbeck’s Arch Surg. 2015;400(8):907–27. https://doi.org/10.1007/s00423-015-1344-5.CrossRef

72.

Yang RL, Freeman K, Reinke CE, Fraker DL, Karakousis GC, Kelz RR, et al. Tertiary hyperparathyroidism in kidney transplant recipients: characteristics of patients selected for different treatment strategies. Transplantation. 2012;94(1):70–6. https://doi.org/10.1097/TP.0b013e3182530699.CrossRefPubMed

73.

Cruzado JM, Moreno P, Torregrosa JV, Taco O, Mast R, Gomez-Vaquero C, et al. A randomized study comparing parathyroidectomy with cinacalcet for treating hypercalcemia in kidney allograft recipients with hyperparathyroidism. J Am Soc Nephrol. 2016;27(8):2487–94. https://doi.org/10.1681/asn.2015060622.CrossRefPubMed

74.

Ivarsson KM, Akaberi S, Isaksson E, Reihner E, Rylance R, Prutz KG, et al. The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dialy Transplant. 2015;30(12):2027–33. https://doi.org/10.1093/ndt/gfv334.CrossRef

75.

Komaba H, Taniguchi M, Wada A, Iseki K, Tsubakihara Y, Fukagawa M. Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int. 2015;88(2):350–9. https://doi.org/10.1038/ki.2015.72.CrossRefPubMed

76.

Sharma J, Raggi P, Kutner N, Bailey J, Zhang R, Huang Y, et al. Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am College Surg. 2012;214(4):400–7. https://doi.org/10.1016/j.jamcollsurg.2011.12.046 (discussion 7-8).CrossRef

77.

Chen J, Jia X, Kong X, Wang Z, Cui M, Xu D. Total parathyroidectomy with autotransplantation versus subtotal parathyroidectomy for renal hyperparathyroidism: a systematic review and meta-analysis. Nephrology (Carlton, Vic). 2017;22(5):388–96. https://doi.org/10.1111/nep.12801.CrossRef

78.

Rothmund M, Wagner PK, Schark C. Subtotal parathyroidectomy versus total parathyroidectomy and autotransplantation in secondary hyperparathyroidism: a randomized trial. World J Surg. 1991;15(6):745–50.CrossRefPubMed

79.

Nicholson ML, Veitch PS, Feehally J. Parathyroidectomy in chronic renal failure: comparison of three operative strategies. J R Coll Surg Edinb. 1996;41(6):382–7.PubMed

80.

Isaksson E, Ivarsson K, Akaberi S, Muth A, Prutz KG, Clyne N, et al. Total versus subtotal parathyroidectomy for secondary hyperparathyroidism. Surgery. 2019;165(1):142–50. https://doi.org/10.1016/j.surg.2018.04.076.CrossRefPubMed

81.

Triponez F, Dosseh D, Hazzan M, Noel C, Soudan B, Lokey J, et al. Accuracy of intra-operative PTH measurement during subtotal parathyroidectomy for tertiary hyperparathyroidism after renal transplantation. Langenbeck’s Arch Surg. 2006;391(6):561–5. https://doi.org/10.1007/s00423-006-0070-4.CrossRef

82.

Ohe MN, Santos RO, Kunii IS, Carvalho AB, Abrahao M, Neves MC, et al. Intraoperative PTH cutoff definition to predict successful parathyroidectomy in secondary and tertiary hyperparathyroidism. Braz J Otorhinolaryngol. 2013;79(4):494–9. https://doi.org/10.5935/1808-8694.20130088.CrossRefPubMed

83.

Ikeda Y, Kurihara H, Morita N, Miyabe R, Takami H. The role of quick bio-intact PTH(1–84) assay during parathyroidectomy for secondary hyperparathyroidism. J Surg Res. 2007;141(2):306–10. https://doi.org/10.1016/j.jss.2006.11.025.CrossRefPubMed

84.

Bieglmayer C, Kaczirek K, Prager G, Niederle B. Parathyroid hormone monitoring during total parathyroidectomy for renal hyperparathyroidism: pilot study of the impact of renal function and assay specificity. Clin Chem. 2006;52(6):1112–9. https://doi.org/10.1373/clinchem.2005.065490.CrossRefPubMed

85.

Freriks K, Hermus AR, de Sevaux RG, Bonenkamp HJ, Biert J, den Heijer M, et al. Usefulness of intraoperative parathyroid hormone measurements in patients with renal hyperparathyroidism. Head Neck. 2010;32(10):1328–35. https://doi.org/10.1002/hed.21328.CrossRefPubMed

86.

Vulpio C, Bossola M, Di Stasio E, Pepe G, Nure E, Magalini S, et al. Intra-operative parathyroid hormone monitoring through central laboratory is accurate in renal secondary hyperparathyroidism. Clin Biochem. 2016;49(7–8):538–43. https://doi.org/10.1016/j.clinbiochem.2016.01.012.CrossRefPubMed

87.

Lau WL, Obi Y, Kalantar-Zadeh K. Parathyroidectomy in the management of secondary hyperparathyroidism. Clin J Am Soc Nephrol. 2018;13(6):952–61. https://doi.org/10.2215/cjn.10390917.CrossRefPubMedPubMedCentral

88.

Numano M, Tominaga Y, Uchida K, Orihara A, Tanaka Y, Takagi H. Surgical significance of supernumerary parathyroid glands in renal hyperparathyroidism. World J Surg. 1998;22(10):1098–102 (discussion 103).CrossRefPubMed

89.

Carter WB, Carter DL, Cohn HE. Cause and current management of reoperative hyperparathyroidism. Am Surg. 1993;59(2):120–4.PubMed

90.

Pham TH, Sterioff S, Mullan BP, Wiseman GA, Sebo TJ, Grant CS. Sensitivity and utility of parathyroid scintigraphy in patients with primary versus secondary and tertiary hyperparathyroidism. World J Surg. 2006;30(3):327–32. https://doi.org/10.1007/s00268-005-0279-3.CrossRefPubMed

91.

de la Rosa A, Jimeno J, Membrilla E, Sancho JJ, Pereira JA, Sitges-Serra A. Usefulness of preoperative Tc-mibi parathyroid scintigraphy in secondary hyperparathyroidism. Langenbeck’s Arch Surg. 2008;393(1):21–4. https://doi.org/10.1007/s00423-007-0151-z.CrossRef

92.

Gasparri G, Camandona M, Bertoldo U, Sargiotto A, Papotti M, Raggio E, et al. The usefulness of preoperative dual-phase 99mTc MIBI-scintigraphy and IO-PTH assay in the treatment of secondary and tertiary hyperparathyroidism. Ann Surg. 2009;250(6):868–71. https://doi.org/10.1097/SLA.0b013e3181b0c7f4.CrossRefPubMed

93.

Alkhalili E, Tasci Y, Aksoy E, Aliyev S, Soundararajan S, Taskin E, et al. The utility of neck ultrasound and sestamibi scans in patients with secondary and tertiary hyperparathyroidism. World J Surg. 2015;39(3):701–5. https://doi.org/10.1007/s00268-014-2878-3.CrossRefPubMed

94.

Ishani A, Liu J, Wetmore JB, Lowe KA, Do T, Bradbury BD, et al. Clinical outcomes after parathyroidectomy in a nationwide cohort of patients on hemodialysis. Clin J Am Soc Nephrol. 2015;10(1):90–7. https://doi.org/10.2215/cjn.03520414.CrossRefPubMed

95.

Mittendorf EA, Merlino JI, McHenry CR. Post-parathyroidectomy hypocalcemia: incidence, risk factors, and management. Am Surg. 2004;70(2):114–9 (discussion 9-20).PubMed

96.

Goldfarb M, Gondek SS, Lim SM, Farra JC, Nose V, Lew JI. Postoperative hungry bone syndrome in patients with secondary hyperparathyroidism of renal origin. World J Surg. 2012;36(6):1314–9. https://doi.org/10.1007/s00268-012-1560-x.CrossRefPubMed

97.

Ho LY, Wong PN, Sin HK, Wong YY, Lo KC, Chan SF, et al. Risk factors and clinical course of hungry bone syndrome after total parathyroidectomy in dialysis patients with secondary hyperparathyroidism. BMC Nephrol. 2017;18(1):12. https://doi.org/10.1186/s12882-016-0421-5.CrossRefPubMedPubMedCentral

98.

Schwarz A, Rustien G, Merkel S, Radermacher J, Haller H. Decreased renal transplant function after parathyroidectomy. Nephrol Dial Transplant. 2007;22(2):584–91. https://doi.org/10.1093/ndt/gfl583.CrossRefPubMed

Title: Management of Post-transplant Hyperparathyroidism and Bone Disease
Authors: Rowena Delos Santos
Ana Rossi
Daniel Coyne
Thin Thin Maw
Publication date: 01-04-2019
Publisher: Springer International Publishing
Keywords: Hyperparathyroidism
Parathyroidectomy
Parathyroidectomy
Hypercalcemia
Hypocalcemia
Cinacalcet
Calcimimetic
Published in: Drugs / Issue 5/2019
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-019-01074-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Management of Post-transplant Hyperparathyroidism and Bone Disease

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2019

Correction to: Triamcinolone Acetonide Extended-Release: A Review in Osteoarthritis Pain of the Knee

Toripalimab: First Global Approval

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease

Correction to: Fremanezumab: First Global Approval

Correction to: Tapentadol Prolonged Release: A Review in Pain Management

Treatment of Vulvodynia: Pharmacological and Non-Pharmacological Approaches